This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nunez, E. Articles by Frohlich, E. D. Search for Related Content PubMed PubMed Citation Articles by Nunez, E. Articles by Frohlich, E. D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Pressure Medicines Hazardous Substances DB ENALAPRIL MALEATE LOSARTAN POTASSIUM

(Hypertension. 1997;29:519.)
© 1997 American Heart Association, Inc.

State-of-the-Art-Lecture

Enalapril and Losartan Reduced Cardiac Mass and Improved Coronary Hemodynamics in SHR

Eduardo Nunez; Kazuyoshi Hosoya; Dinko Susic; Edward D. Frohlich

From Hypertension Research Laboratories, Alton Ochsner Medical Foundation, New Orleans, LA.

Correspondence to Edward D. Frohlich, MD, Vice President for Academic Affairs, Alton Ochsner Medical Foundation, 1516 Jefferson Hwy, New Orleans, LA 70121

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Among the multiple mechanisms postulated for the increased risk of hypertensive left ventricular hypertrophy (LVH), coronary hemodynamic alterations remain a strong possibility. This study was designed to compare the effects of treatment with an ACE inhibitor (enalapril) and an angiotensin AT₁ receptor antagonist (losartan) on systemic and coronary hemodynamics and to determine whether the combination of these two renin-angiotensin system (RAS) inhibitors would be as or more effective in reducing mean arterial pressure (MAP), left ventricular (LV) mass, and improving coronary hemodynamics than either regimen alone. Thus, 23 week old spontaneously hypertensive rats (SHR) were treated (12 weeks) with tap water (C), enalapril (30 mg·kg^-1· d^-1), losartan (30 mg·kg^-1·d^-1), or combination (15 mg·kg^-1 ·d^-1). Age-matched Wistar-Kyoto (WKY) rats served as normotensive controls. After 12 weeks, systemic and coronary hemodynamics were determined (15 µm radiolabeled microspheres) at baseline, during maximal treadmill exercise, and during maximal dilation (dipyridamole). Enalapril and losartan equally reduced MAP and LV mass in association with a decreased total peripheral resistance. The RAS combination reduced MAP and LV mass more than either drug alone. Resting cardiac index and coronary blood flow (CBF) per unit of LV mass did not differ among the groups. Although enalapril did not improve coronary flow reserve (CFR), it diminished minimal coronary vascular resistance (MCVR); losartan improved both. However, the combination was more effective than either agent alone, reaching values close to normotensive WKY controls. In conclusion, these data demonstrated significantly impaired maximal CBF, CFR, and MCVR in untreated SHR, but losartan alone and in combination with enalapril improved systemic and coronary hemodynamics more than enalapril alone.

Key Words: left ventricular hypertrophy [reversal] • angiotensin II [antagonism and inhibition] • drug synergism • losartan • enalapril • coronary circulation • spontaneously hypertensive rats

Abbreviations: CBF = coronary blood flow • CFR = coronary flow reserve • CO = cardiac output • CVR = coronary vascular resistance • CVRI = coronary vascular resistance index • LV = left ventricular/ventricle • LVH = LV hypertrophy • MAP = mean arterial pressure • MCVR = minimal coronary vascular resistance • RV = right ventricular/ventricle • SHR = spontaneously hypertensive rats • SHR-C = SHR controls • SHR-E = enalapril-treated controls • SHR-E&L = combination-treated controls • SHR-L = losartan-treated controls • TPRI = total peripheral resistance index • WKY = Wistar-Kyoto • WKY-C = WKY controls

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Left ventricular hypertrophy resulting from hypertension is an independent risk factor for premature cardiovascular morbidity and mortality,^1–3 although LVH reversal has not yet been shown to reduce that risk.⁴ LVH has been associated with impaired coronary hemodynamics in experimental animals^5,6 and patients.^7–9 Among the postulated mechanisms offered to explain the increased risk are altered coronary hemodynamics, including decreased CBF and CFR, increased resting and MCVR, and altered viscosity; cardiac arrhythmias; cardiac failure; and accelerated atherosclerosis of epicardial arteries.¹⁰ Current goals of antihypertensive therapy have been directed toward optimal control of arterial pressure, although reversal of LVH and improvement of the compromised coronary hemodynamics are the subject of intense investigation directed toward reducing LVH risk.⁴ Accordingly, this study was designed to determine whether treatment with an ACE inhibitor (enalapril), an AT₁ receptor antagonist (losartan), or their combination improved coronary hemodynamics in association with reduced LV mass.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Procedures
Male SHR and normotensive WKY rats were obtained from Charles River Breeding Laboratories Inc (Wilmington, Mass) at 14 weeks of age and were maintained thereafter in accordance with our institutional animal care committee guidelines after prior approval of the experimental protocol. They were housed in temperature-controlled rooms on a 12-hour light/dark cycle and were fed usual rat chow and water ad libitum. At 23 weeks of age, the rats were randomly assigned to one of five groups of 16 rats each: untreated normotensive WKY-C (tap water), untreated SHR-C (tap water), SHR-E (30 mg·kg^-1·d^-1 by gavage), SHR-L (30 mg·kg^-1· d^-1 by gavage), and SHR-E&L (5 mg·kg^-1 ·d^-1 of each agent by gavage). The rats followed their respective treatments for 12 weeks. All rats were trained to run on a motor-driven treadmill (Columbus Instruments) at speeds ranging from 0.5 to 1.0 m/min, 0% grade, for 5 min/d for 2 to 3 days a week during the final 2 weeks of the protocol to familiarize them with treadmill running.¹¹

At 35 weeks of age, the rats were instrumented for determination of systemic and coronary hemodynamics using the reference standard microsphere method as described previously by our laboratory.^12,13 Thus, under ketamine (10 mg/kg) and acepromazine (50 mg/kg) anesthesia, they were cannulated with three polyethylene catheters (PE-50): one inserted into the LV (via right carotid artery) for injection of microspheres, a second inserted into the caudal (tail) artery for arterial pressure measurement and for reference sample withdrawal, and a third inserted into a jugular vein for dipyridamole infusion. These catheters were exteriorized at the nape of the neck and filled with heparinized saline solution (200 U/mL), and the rats were returned to their nonrestrictive plastic cages to recover fully over at least 3 hours. Radiolabeled (⁵⁷Co, ¹¹³Sn, and ⁴⁶Sc) microspheres (DuPont) of 15-µm diameter were used for each blood flow measurement. Thus, 100 000 microspheres, suspended in 0.045 mL saline containing <0.01% Tween 80, were infused into the LV over 5 seconds, followed by 0.5 mL warm saline flush injection over 15 seconds. Before infusion, the microsphere suspension was mixed thoroughly on a touch mixer (Vortex) for 1 to 2 minutes; during the infusion, the Silastic tube containing the microsphere suspension was constantly tapped to ensure even distribution. The reference sample was withdrawn at a rate of 0.45 mL/min over 60 seconds (including 10 seconds before and 20 seconds after injection). Efficacy of microsphere-blood mixing was assessed by comparing blood flows to the right and left kidneys; a difference of BORDER="0">15% for these two flows was considered unacceptable, and the study was excluded. Adequate trapping of microspheres was evaluated by counting lung radioactivity; and if the percentage of blood flow to the lungs was 5% or greater (excessive AV shunt), the rat was also eliminated from the study.^14,15 At the end of the study, the rat was killed with an overdose of pentobarbital, and the heart was removed immediately. After the atria was discarded, the free wall of the RV was carefully removed, leaving the LV free wall and septum as total LV weight. Further, the LV was dissected into two segments, subepicardium and subendocardium, to assess regional myocardial perfusion. These segments were carefully cleaned, blotted dry, and weighed on a precision grammatic balance. Ventricular weights were normalized for body weight and expressed as RV and LV mass (mg/g). A fixed segment (4.5 cm) of the descending aorta, starting at a point distal to the subclavian artery, was removed, weighed, and expressed as aortic mass index (mg·mm^-2 ·g^-1). Tissue samples, as well as the blood reference sample, were placed in plastic scintillation vials and counted for 15 minutes in a deep-well gamma scintillation spectrometer (Packard) using a multichannel analyzer.

CO and CBF were calculated from the counts per minute and the sample wet weights according to standard procedures after appropriate corrections for decay and background. Spillover correction between channels was achieved using matrix inversion software (Compusphere; Packard). Thus, CO and the CBF were calculated using these formulas: CO (mL/min)=I (cpm)xSR (mL/min)/RS(cpm) and CBF (mL/min)=LV (cpm)xSR (mL/ min)/RS (cpm), where I is total radioactivity injected and was calculated as the difference in counts in the tubing before and after injection of the microspheres, RS is counts in the reference blood sample, SR is rate of withdrawal from the reference arteries, and LV is LV count. Cardiac index and TPRI were calculated and expressed as mL/min/kg and U, respectively. CVR was calculated by dividing mean arterial pressure (MAP), recorded just before each microsphere injection, by its corresponding CBF. The CBF and CVR were normalized with respect to RV and LV weight (CBF per gram of myocardium and CVRI) and expressed as mL/ min/gm and U, respectively. A total of 18 rats were discarded from the study because of unsuccessful cannulation, uneven microsphere distribution to both kidneys, or pulmonary AV shunting.

Protocol
After full recovery from anesthesia, the rats were studied while unrestrained in a open-top plastic cage. Both the caudal arterial and LV catheters were connected to Gould-Statham pressure transducers (P23D by Statham Instruments). MAP and HR were recorded throughout the study on a multichannel physiograph coupled with a cardiotachometer (Sensor Medics R612). Baseline (control) measurements were obtained after 30 minutes of hemodynamic stabilization using a first microsphere (⁵⁷Co) injection. After these baseline measurements were obtained, each rat ran on the treadmill starting at a speed of 0.4 m/s that was increased at a rate of 0.15 m/s every minute until exhaustion, indicated by inability to maintain a pace with the treadmill.^11,13 The second microsphere (¹¹³Sn) injection was given at the peak of maximal exercise. Then, after full recovery from exercise (60 minutes), maximal coronary vasodilatation was produced by dipyridamole, administered (4 mg·kg^-1 ·min^-1 IV for 10 minutes) using a Harvard infusion/withdrawal pump (Harvard Apparatus).¹⁶ Maximal CBF then was determined by injecting the third radionuclide microsphere (⁴⁶Sc) while the dipyridamole was infused continually for 1 to 2 minutes after the microspheres were injected.

Statistical Analysis
All results are expressed as mean±SEM. The paired Student’s t test was used for group comparisons (baseline versus treadmill or baseline versus dipyridamole). Single-factor ANOVA was carried out to assess differences between treatment groups.¹⁷ The mean change from baseline (with treadmill or dipyridamole) is expressed as a CVR and was tested for statistical significance using ANCOVA with treatment group as a factor and the baseline as a covariate.¹⁸ When the F statistic from ANOVA or ANCOVA was significant, pairwise comparisons were made using the Student-Newman-Keuls post-hoc test to adjust for multiplicity of testing.¹⁹ Correlation co-efficients were computed using a least-squares linear regression analysis.¹⁷ Data analysis and calculations were accomplished by JMP version 3.1.5 statistical software (SAS Institute Inc). The level of significance was defined at an .05.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Body, Aortic, and Cardiac Mass
Body weight was significantly less in untreated SHR than normotensive WKY-C (P<.05); however, there were no differences among the treated SHR groups with respect to the untreated SHR (Table 1). There were no differences in RV mass among the WKY and SHR untreated groups; however, it was significantly reduced in the three treated groups (Table 1). Aortic mass index was significantly lower in the WKY-C than the SHR-C; and all treatments diminished aortic mass index in SHR groups (without differences between treatment groups). LV mass was markedly increased in untreated SHR rats (compared with WKY (P<.01) and all three SHR treatment groups (P<.01, each group). The combination therapy reduced LV mass (by 21%) more than enalapril (17%; P<.05) or losartan (15%; P<.01) alone. LV mass and MAP of the SHR control and treatment groups were directly correlated (r=.670, P<.01).

View this table: [in this window] [in a new window]   TABLE 1. Body Weight Aortic and Cardiac Mass Indexes After 12 Weeks of Treatment With Enalapril (30 mg·kg-1· d-1), Losartan (30 mg·kg-1 ·d-1), or Their Combination (15 mg·kg-1·d-1)

Systemic Hemodynamics
MAP and TPRI were significantly increased in the SHR-C (148±5 versus 98±6 mm Hg, P<.01, and 0.385±0.032 versus 0.240±0.015 U, P<.01, respectively) with respect to the WKY-C. Moreover, MAP was reduced by enalapril (20%, P<.01), losartan (20%, P<.01), and their combination (34%, P<.01); the latter was reduced more than either drug alone (P<.05). This MAP reduction was achieved through a significant decrease in TPRI; there were no differences between groups in heart rate or cardiac index (Table 2).

View this table: [in this window] [in a new window]   TABLE 2. Systemic and Coronary Hemodynamic Effects of Enalapril (30 mg·kg-1·d-1), Losartan (30 mg·kg-1·d-1), and Their Combination (15 mg·kg-1 ·d-1) Aftent

Coronary Hemodynamics
Resting CBF (per unit of RV and LV mass) did not differ among the various SHR groups. Because MAP was lower in WKY-C and was significantly reduced by treatment in the SHR groups, CVRI was also reduced in these groups. However, only the untreated WKY and the combination treatment were significantly lower than the SHR-C (both P<.01). The distribution of CBF in subendocardial and subepicardial layers (expressed as a ratio) showed no differences among the groups (Table 2).

Exercise and Dipyridamole Interventions
MAP was reduced in all groups except SHR-C by dipyridamole (P<.01) and with treatmill exercise (Table 3). Treadmill exercise induced a moderate but significant fall in TPRI that was associated with a slightly faster heart rate in all treated groups; however, only the group receiving both enalapril and losartan achieved significant increases in both heart rate and cardiac index. Dipyridamole infusion increased LV CBF in all groups (P<.01) except the SHR-C. CBF reserve (defined as the difference between maximal CBF achieved with dipyridamole and the basal CBF) was significantly greater with SHR-L and SHR-E&L (3.23±0.68 mL·min^-1)·g^-1, P<.05, and 3.80±0.45 mL·min^-1 ·g^-1, P<.01, respectively) than in the SHR-C (1.47±0.39 mL · min^-1·g^-1). CVRI was reduced in all groups by dipyridamole (P<.01 for each); however, the CVR (expressed as the ratio between MCVR and CVRI at baseline) was significantly reduced by SHR-L and SHR-E&L (0.55±0.06, P<.05, and 0.52±0.04, P<.01, respectively) in comparison with the SHR-C (0.67±0.05). Minimal CVR, achieved after maximal dilation with dipyridamole, was reduced in all three treatment groups as well as with the WKY-C (P<.01 for each). During treadmill exercise, there was a similar trend in coronary hemodynamics, although exercise was far less effective than pharmacological intervention (Table 4). Finally, LV CFR with dipyridamole was inversely related to basal MAP and LV mass (r=-0.40, P<.01, and r=-.43, P<.01, respectively).

View this table: [in this window] [in a new window]   TABLE 3. Systemic Hemodynamic Indices Obtained After Treadmill Exercise or Dipyridamole Infusion

View this table: [in this window] [in a new window]   TABLE 4. LV Coronary Hemodynamic Indexes Obtained After Treadmill Exercise or Dipyridamole Infusion

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
The results of this study demonstrated that long-term AT₁ receptor blockade alone or in combination with ACE inhibition was effective in improving coronary hemodynamics associated with reduction in cardiac mass related to LVH. Three lines of evidence support this conclusion: (1) enalapril and losartan equally reduced MAP and LV mass; (2) the combination of enalapril and losartan (in half-doses of each when used alone) reduced pressure and LV mass more than either drug administered alone; and (3) although enalapril had no effect on coronary hemodynamics, only losartan or the combination was more effective in normalizing coronary hemodynamics (to a values closer to that of normotensive WKY).

ACE inhibitors as well as AT₁ receptor antagonists are extremely effective in reducing arterial pressure; however, it is not clear why the simultaneous use of both agents was more effective than either agent when used alone in twice the dose of each. Furthermore, this greater effect of the combined therapy was reduced LV mass more than either drug when used alone. Prior studies from our and other laboratories using ACE inhibitors^20–24 demonstrated reduction of cardiac mass even when arterial pressure was suboptimally reduced, suggesting nonhemodynamic effects of inhibition of the generation of angiotensin II^{20,21,25–27} or an additional effect of kinins associated with ACE inhibition.^28–32 However, the latter mechanism seems less likely to be operative in the present study since losartan was at least equally as effective or more effective than enalapril when either was used alone. Supporting the primary hemodynamic effect of losartan in reducing LV mass (as opposed to a nonhemodynamic action) are the findings that AT₂ receptors in contrast to the AT₁ receptors mediate the mitogenic effects of angiotensin II.^33,34 And further support of this line of reasoning is the highly positive correlation that we demonstrated between LV mass and MAP (r=.67, P<.01), although nonhemodynamic factors may still participate. Thus, enalapril and losartan equally reduced RV mass, although the combination treatment was even more effective (Table 1). This reduction in overall cardiac mass may also be related to a decrease in LV and RV wall collagen content; and while this was not determined in this study, we did show in earlier work that ACE inhibition did in fact diminish RV as well as LV collagen.^35,36

The present study also demonstrated that associated with the reduction in MAP and LV mass, losartan improved coronary hemodynamics, although the combination with enalapril was even more effective. As already stated, hypertensive LVH is associated with impaired coronary hemodynamics, manifested by reduced CBF, reduced CFR, elevated MCVR, and abnormal subendocardial autoregulation.^5–9 Reduced CFR in LVH has been attributed to structural alterations of the coronary resistance vessels (vascular component) manifested by a reduction in reduced arterial vascularity, capillary density, and decreased total cross-sectional area of resistance vessels.^37–41 The myocardial component in LVH may also contribute to an extravascular component of the increased CVR that is manifested by forces related to myocardial contraction and relaxation and by interstitial and perivascular myocardial fibrosis.^41,42 In addition, attenuation of endothelially mediated control of CVR may also exist. Recent studies have demonstrated impaired endothelially dependent coronary vasodilatation in response to acetylcholine in hypertensive patients,^43–45 although enhanced activity of endothelium-derived vasoconstricting factor may also be an operating mechanism.⁴⁶ Additionally, several reports have suggested that abnormalities in coronary circulation persist even after LVH reversal and MAP reduction, suggesting a dissociation between LV mass and coronary vessel abnormalities in response to antihypertensive treatment.^21,47,48 In support of this thesis is a recent study from our laboratory that was conducted with the same protocol used in the present study. In that study, we demonstrated that losartan administered for only 3 weeks did not demonstrate a significant improvement in overall coronary hemodynamics, although the reductions in MAP (23%) and LV mass (19%) were comparable to the present study.¹³ Thus, the results of the present study indicate that more than 3 weeks of treatment was necessary to improve all coronary hemodynamics and indexes (Table 4), a finding that may explain negative results in short-term trials. On the other hand, we deliberately used a 3-week treatment period in our earlier studies to dissociate hemodynamic from nonhemodynamic effects produced by antihypertensive therapy.^20–22,46 Thus, the present findings also support the hypothesis that angiotensin II, through its effects on AT₁ receptors, may participate importantly in reducing the CBF reserve associated with LVH. However, by adding enalapril to the losartan (even in half doses of each), the coronary hemodynamic effects were improved further and more significantly. This could be explained by the dual effects of inhibiting the renin-angiotensin system and the additional effect of ACE inhibition on increasing the role of kinins. This concept is supported by the finding that losartan, after 12 weeks of treatment, normalized MAP, reduced LV mass, and improved coronary hemodynamics, although not to the extent achieved in combination with enalapril. Finally, it is important to recognize that despite the controlled MAP, reduction in LV mass, and improved coronary hemodynamics associated with AT₁ receptor antagonism, reduction in cardiac risk was not a feature of the present experimental design.

	Acknowledgments

 
This work was supported in part by a grant-in-aid from Merck Research Laboratories, West Point, Penn. We acknowledge the technical assistance of Jane Nunez.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease: the Framingham Heart Study. Ann Intern Med. 1970; 72 : 813 –822.[Abstract/Free Full Text]

2. Casale PN, Devereaux RB, Milner M, Zullo G, Harschfield GA, Pickering TG, Laragh JH. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med. 1986; 105 : 173 –178.[Abstract/Free Full Text]

3. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990; 322 : 1561 –1566.[Abstract]

4. Susic D, Nunez E, Frohlich ED. Reversal of hypertrophy: an active biologic process. Curr Opin Cardiol. 1995; 10 : 466 –472.[Medline] [Order article via Infotrieve]

5. Marcus ML, Mueller TM, Gascho JA, Kerber RE. Effect of cardiac hypertrophy secondary to hypertension on the coronary circulation. Am J Cardiol. 1979; 44 : 1023 –1028.[Medline] [Order article via Infotrieve]

6. Sato F, Isoyama S, Takishima T. Normalization of impaired coronary circulation in hypertrophied rat hearts. Hypertension. 1990; 16 : 26 –34.[Medline] [Order article via Infotrieve]

7. Pichard AD, Frolin R, Smith H, Ambrose J, Meller J. Coronary flow studies in patients with left ventricular hypertrophy of the hypertensive type: evidence for an impaired coronary vascular reserve. Am J Cardiol. 1981; 47 : 547 –554.[Medline] [Order article via Infotrieve]

8. Opherk D, Mall G, Zebe H, Schwartz F, Weihe E, Manthey J, Kübler W. Reduction of coronary reserve: a mechanism for angina pectoris in patients with arterial hypertension and normal coronary arteries. Circulation. 1984; 69 : 1 –7.[Abstract/Free Full Text]

9. Motz W, Strauer BE. Improvement of coronary flow reserve after long-term therapy with enalapril. Hypertension. 1996; 27 : 1031 –1038.[Abstract/Free Full Text]

10. Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, Fauad-Tarazi F, Horan MJ, Marcus M, Massie B, Pfeffer MA, Re RN, Roccella EJ, Savage D, Shub C. The heart in hypertension. N Engl J Med. 1992; 327 : 998 –1008.[Medline] [Order article via Infotrieve]

11. Soria F, Frohlich ED, Aristizabal D, Kaneko K, Kardon MB, Hunter J, Pegram BL. Preserved cardiac performance after quinapril-induced left ventricular mass reversal in spontaneously hypertensive rats. J Hypertens. 1994; 12 : 585 –589.[Medline] [Order article via Infotrieve]

12. Ishise S, Pegram BL, Yamamoto J, Kitamura Y, Frohlich ED. Reference sample microsphere method: cardiac output and blood flows in conscious rat. Am J Physiol. 1980; 239 : H443 –H449.[Medline] [Order article via Infotrieve]

13. Kaneko K, Susic D, Nunez E, Frohlich ED. Losartan reduces cardiac mass and improves coronary flow reserve in the spontaneously hypertensive rat. J Hypertens. 1996; 14 : 645 –653.[Medline] [Order article via Infotrieve]

14. Pfeffer MA, Pfeffer JM, Dunn FG, Nishiyama K, Tsuchiya M, Frohlich ED. Natural biventricular hypertrophy in normotensive rats, I: physical and hemodynamic characteristics. Am J Physiol. 1973; 236 : H640 –H643.

15. Sesoko S, Pegram BL, Kuwajima I, Frohlich ED. Hemodynamic studies in spontaneously hypertensive rats with congenital arteriovenous shunts. Am J Physiol. 1982; 242 : H722 –H725.[Medline] [Order article via Infotrieve]

16. Chilian WM, Wangler RD, Peters KG, Tomanek RJ, Marcus ML. Thyroxine induced left ventricular hypertrophy in the rat: anatomical and physiological evidence for angiogenesis. Circ Res. 1985; 57 : 591 –598.[Abstract/Free Full Text]

17. Armitage P, Berry G. Statistical Methods in Medical Research. 3rd ed. Oxford, UK: Blackwell Scientific Publications; 1994 .

18. Frison L, Pocock SJ. Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. Stat Med. 1992; 11 : 1685 –1704.[Medline] [Order article via Infotrieve]

19. Ludbrook J. Repeated measurements and multiple comparisons in cardiovascular research. Cardiovasc Res. 1994; 28 : 303 –311.[Free Full Text]

20. Frohlich ED, Horinaka S. Cardiac and aortic effects of angiotensin converting enzyme inhibitors. Hypertension. 1991; 18 (suppl II): II-2 –II-7.[Medline] [Order article via Infotrieve]

21. Frohlich ED, Sasaki O. Dissociation of changes in cardiovascular mass and performance in angiotensin converting enzyme inhibitor in Wistar-Kyoto and spontaneously hypertensive rats. J Am Coll Cardiol. 1990; 16 : 1492 –1499.[Abstract]

22. Ando K, Frohlich ED, Chien Y, Pegram BL. Effects of quinapril on systemic and regional hemodynamics and cardiac mass in spontaneously hypertensive and Wistar-Kyoto rats. J Vasc Med Biol. 1991; 3 : 117 –123.

23. Morgan HE, Baker KM. Cardiac hypertrophy: mechanical, neural, and endocrine dependence. Circulation. 1991; 83 : 13 –26.[Free Full Text]

24. Zierhut W, Zimmer HG, Gerdes AM. Effect of angiotensin converting enzyme inhibition on pressure-induced left ventricular hypertrophy in rats. Circ Res. 1991; 69 : 609 –617.[Abstract/Free Full Text]

25. Tarazi RC, Frohlich ED. Is reversal of cardiac hypertrophy a desirable goal of antihypertensive therapy? Circulation. 1987; 75 (suppl I): I-113 –I-117.[Medline] [Order article via Infotrieve]

26. Frohlich ED. Overview of hemodynamic and non-hemodynamic factors associated with LVH. J Mol Cell Cardiol. 1989; 21 : 3 –10.

27. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine: a paradigm shift? Circulation. 1994; 89 : 493 –498.[Free Full Text]

28. Wiemer G, Schölkens BA, Becker RHA, Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension. 1991; 18 : 558 –563.[Abstract/Free Full Text]

29. Cachofeiro V, Sakakibara T, Nasjletti A. Kinins, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension. Hypertension. 1992; 19 : 138 –145.[Abstract/Free Full Text]

30. Gohlke P, Linz W, Schölkens BA, Kuwer I, Bartenbach S, Schnell A, Unger T. Angiotensin-converting enzyme inhibition improves cardiac function: role of bradykinin. Hypertension. 1994; 23 : 411 –418.[Abstract/Free Full Text]

31. Scicli AG. Increases in cardiac kinins as a new mechanism to protect the heart. Hypertension. 1994; 23 : 419 –421.[Free Full Text]

32. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995; 47 : 25 –49.[Abstract]

33. Dzau VJ, Sasamura H, Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens. 1993; 11 (suppl 3): 13 –18.[Medline] [Order article via Infotrieve]

34. Dzau VJ, Mukoyama M, Pratt RE. Molecular biology of angiotensin receptors: target for drug research? J Hypertens. 1994; 12 (suppl 2): 1 –5.[Medline] [Order article via Infotrieve]

35. Arita M, Horinaka S, Frohlich ED. Biochemical components and myocardial performance after reversal of left ventricular hypertrophy in spontaneously hypertensive rats. J Hypertens. 1993; 11 : 951 –959.[Medline] [Order article via Infotrieve]

36. Arita M, Horinaka S, Komatsu K, Frohlich ED. Reversal of left ventricular hypertrophy with different classes of drugs causes differing ventricular biochemical changes. J Hypertens. 1993; 11 : S354 –S355.

37. Folkow B. Physiological aspects of primary hypertension. Physiol Rev. 1982; 62 : 347 –467.[Free Full Text]

38. Motz W, Strauer BE. Regression of structural cardiovascular changes by antihypertensive therapy. Hypertension. 1984; 6 (suppl III): III-133 –III-139.[Medline] [Order article via Infotrieve]

39. Tomanek RJ, Palmer PY, Pfeiffer GL, et al. Morphometry of canine coronary arteries, arterioles and capillaries during hypertension and left ventricular hypertrophy. Circ Res. 1986; 58 : 38 –46.[Abstract/Free Full Text]

40. Anderson PG, Bishop SP, Digerness SB. Vascular remodeling and improvement of coronary reserve after hydralazine treatment in spontaneously hypertensive rats. Circ Res. 1989; 64 : 1127 –1136.[Abstract]

41. Schwartzkopff B, Motz W, Knauer S, Frenzel H, Strauer BE. Morphometric investigation of intramyocardial arterioles in right septal endomyocardial biopsy of patients with arterial hypertension and left ventricular hypertrophy. J Cardiovasc Pharmacol. 1992; 20 (suppl 1): S12 –S17.[Medline] [Order article via Infotrieve]

42. Nitenberg A, Antony I. Epicardial coronary arteries are not adequately sized in hypertensive patients. J Am Coll Cardiol. 1996; 27 : 115 –123.[Abstract]

43. Bossaller C, Auch-Schwelk W, Weber F, Götze S, Graöfe M, Graf K, Fleck E. Endothelium-dependent relaxation are augmented in rats chronically treated with the angiotensin-converting enzyme inhibitor enalapril. J Cardiovas Pharmacol. 1992; 20 (suppl 9): S91 –S95.

44. Kelm M, Feelisch M, Krebber T, DeuBen A, Motz W, Strauer BE. Role of nitric oxide in the regulation of coronary vascular tone in hearts from hypertensive rats: maintenance of nitric oxide-forming capacity and increased basal production of nitric oxide. Hypertension. 1995; 25 : 186 –193.[Abstract/Free Full Text]

45. Tschudi MR, Criscione L, Novosel D, Pfeiffer K, Lüscher TF. Anti-hypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats. Circulation. 1994; 89 : 2212 –2218.[Abstract/Free Full Text]

46. Tschudi MR, Lüscher TF. Age and hypertension differently affect coronary contractions to endothelin-1, serotonin, and angiotensins. Circulation. 1995; 91 : 2415 –2422.[Abstract/Free Full Text]

47. Sato F, Isoyama S, Takishima T. Normalization of impaired coronary circulation in hypertrophied rat hearts. Hypertension. 1990; 16 : 26 –34.[Medline] [Order article via Infotrieve]

48. Clozel JP, Veniant M, Hess P, Sprecher U. Effects of two angiotensin converting enzyme inhibitors and hydralazine on coronary circulation in hypertensive rats. Hypertension. 1991; 18 (suppl II): II-8 –II-14.[Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				M. J. Soler, M. Ye, J. Wysocki, J. William, J. Lloveras, and D. Batlle Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan Am J Physiol Renal Physiol, February 1, 2009; 296(2): F398 - F405. [Abstract] [Full Text] [PDF]

				X. Zhou, L. C. Matavelli, H. Ono, and E. D. Frohlich Superiority of combination of thiazide with angiotensin-converting enzyme inhibitor or AT1-receptor blocker over thiazide alone on renoprotection in L-NAME/SHR Am J Physiol Renal Physiol, October 1, 2005; 289(4): F871 - F879. [Abstract] [Full Text] [PDF]

				J. Varagic, D. Susic, M. Slama, and E. D. Frohlich Omapatrilat Induces Profound Renal Vasodilation but Does Not Affect Coronary Hemodynamics Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2003; 8(2): 167 - 174. [Abstract] [PDF]

				S. C. Leary, D. Michaud, C. N. Lyons, T. M. Hale, T. L. Bushfield, M. A. Adams, and C. D. Moyes Bioenergetic remodeling of heart during treatment of spontaneously hypertensive rats with enalapril Am J Physiol Heart Circ Physiol, August 1, 2002; 283(2): H540 - H548. [Abstract] [Full Text] [PDF]

				E. D. Frohlich Local Hemodynamic Changes in Hypertension: Insights for Therapeutic Preservation of Target Organs Hypertension, December 1, 2001; 38(6): 1388 - 1394. [Abstract] [Full Text] [PDF]

				D. Susic, J. Varagic, and E. D. Frohlich Isolated Systolic Hypertension in Elderly WKY Is Reversed With L-Arginine and ACE Inhibition Hypertension, December 1, 2001; 38(6): 1422 - 1426. [Abstract] [Full Text] [PDF]

				J. Varagic, D. Susic, and E. D. Frohlich Coronary Hemodynamic and Ventricular Responses to Angiotensin Type 1 Receptor Inhibition in SHR : Interaction With Angiotensin Type 2 Receptors Hypertension, June 1, 2001; 37(6): 1399 - 1403. [Abstract] [Full Text] [PDF]

				E. D Frohlich Review: Promise of prevention and reversal of target organ involvement in hypertension Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S4 - S9. [PDF]

				H.-C. Chen, J. L. Bouchie, A. S. Perez, A. C. Clermont, S. Izumo, J. Hampe, and E. P. Feener Role of the Angiotensin AT1 Receptor in Rat Aortic and Cardiac PAI-1 Gene Expression Arterioscler Thromb Vasc Biol, October 1, 2000; 20(10): 2297 - 2302. [Abstract] [Full Text] [PDF]

				M. S Weinberg, A. J Weinberg, and D. H Zappe Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors Journal of Renin-Angiotensin-Aldosterone System, September 1, 2000; 1(3): 217 - 233. [PDF]

				T. Tamura, S. Said, J. Harris, W. Lu, and A. M. Gerdes Reverse Remodeling of Cardiac Myocyte Hypertrophy in Hypertension and Failure by Targeting of the Renin-Angiotensin System Circulation, July 11, 2000; 102(2): 253 - 259. [Abstract] [Full Text] [PDF]

				J. Higaki, M. Aoki, R. Morishita, I. Kida, Y. Taniyama, N. Tomita, K. Yamamoto, A. Moriguchi, Y. Kaneda, and T. Ogihara In Vivo Evidence of the Importance of Cardiac Angiotensin-Converting Enzyme in the Pathogenesis of Cardiac Hypertrophy Arterioscler Thromb Vasc Biol, February 1, 2000; 20(2): 428 - 434. [Abstract] [Full Text] [PDF]

				P. Madeddu, C. Emanueli, R. Maestri, M. B. Salis, A. Minasi, M. C. Capogrossi, and G. Olivetti Angiotensin II Type 1 Receptor Blockade Prevents Cardiac Remodeling in Bradykinin B2 Receptor Knockout Mice Hypertension, January 1, 2000; 35(1): 391 - 396. [Abstract] [Full Text] [PDF]

				P.A. van Zwieten The influence of antihypertensive drug treatment on the prevention and regression of left ventricular hypertrophy Cardiovasc Res, January 1, 2000; 45(1): 82 - 91. [Abstract] [Full Text] [PDF]

				E. D. Frohlich The necessity for recognition and treatment of patients with "mild" hypertension J. Am. Coll. Cardiol., November 1, 1999; 34(5): 1369 - 1377. [Abstract] [Full Text] [PDF]

				E. D. Frohlich Risk Mechanisms in Hypertensive Heart Disease Hypertension, October 1, 1999; 34(4): 782 - 789. [Abstract] [Full Text] [PDF]

				M. Yoshiyama, K. Takeuchi, T. Omura, S. Kim, H. Yamagishi, I. Toda, M. Teragaki, K. Akioka, H. Iwao, and J. Yoshikawa Effects of Candesartan and Cilazapril on Rats With Myocardial Infarction Assessed by Echocardiography Hypertension, April 1, 1999; 33(4): 961 - 968. [Abstract] [Full Text] [PDF]

				D. Susic, A. Francischetti, and E. D. Frohlich Prolonged L-Arginine on Cardiovascular Mass and Myocardial Hemodynamics and Collagen in Aged Spontaneously Hypertensive Rats and Normal Rats Hypertension, January 1, 1999; 33(1): 451 - 455. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nunez, E. Articles by Frohlich, E. D. Search for Related Content PubMed PubMed Citation Articles by Nunez, E. Articles by Frohlich, E. D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Pressure Medicines Hazardous Substances DB ENALAPRIL MALEATE LOSARTAN POTASSIUM